Your session is about to expire
← Back to Search
Digital Therapeutic
HPDT-DA-013 for Anxiety
N/A
Waitlist Available
Led By Roger Vilardaga, Ph.D.
Research Sponsored by Happify Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, average of 14 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a digital therapeutic program for adults with depression or anxiety. Participants use the program on their devices for a few months, completing activities and assessments to help manage their mental health.
Eligible Conditions
- Anxiety
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, average of 14 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, average of 14 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Generalized Anxiety Disorder-7 (GAD-7)
Patient Health Questionnaire-9 (PHQ-9)
Secondary study objectives
GAD-7
PHQ-9
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Digital therapeuticExperimental Treatment1 Intervention
Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HPDT-DA-013
2021
N/A
~370
Find a Location
Who is running the clinical trial?
Happify Inc.Lead Sponsor
6 Previous Clinical Trials
21,257 Total Patients Enrolled
Roger Vilardaga, Ph.D.Principal InvestigatorDuke University
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger